Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Samsara Inc (IOT) vs Medpace Holdings Inc (MEDP) Price & Performance

Samsara IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Samsara Inc vs Medpace Holdings Inc — how do they compare? Samsara Inc trades at $39.11 (market cap $23.49B), while Medpace Holdings Inc trades at $601.1 (market cap $16.90B). The key difference: Samsara Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Samsara Inc nearer its low. Which is the better fit depends on your goals.

IOTMEDP
Market Cap
$23.49B$16.90B
Sector
TechnologyTechnology
52-Week High
$45.22$620.59
52-Week Low
$24.25$393.42
Enterprise Value
$22.76B$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Samsara Inc

Samsara (IOT) trades at $39.11, down 1.88% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company shows impressive revenue growth, projecting $1.7B for 2026 with a positive net income turnaround to $58M. Recent earnings beats and a 'Moderate Buy' analyst consensus with a $44.50 price target highlight investor confidence in the Connected Operations Platform strategy.

Outlook remains positive with 36.9% upside potential to consensus targets, though elevated P/E ratio of 403.2 and negative 2025 EBITDA pose valuation risks. Key catalysts include continued AI adoption in physical operations and September earnings report, while competition and execution on growth investments represent primary challenges.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Samsara Inc

Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.

Read more on IOT

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP